Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
doi:10.1007/s00210-023-02452-2
The rate increases with higher doses: 12-14% at 0.5 mg, 23-24% at 2.4 mg
Who should exercise particular caution
: CRH
LY3437943 (Retatrutide): discovery to clinical proof of concept (triple GLP-1/GIP/glucagon agonist, preclinical mechanism) Nature Reviews Endocrinology (2024) Multi-receptor agonists for metabolic disease (mechanism of GLP-1/GIP/glucagon co-activation) Diabetes Care (2024) Incretin-based therapies: GLP-1, GIP, and glucagon receptor pharmacology (metabolic pathways, energy expenditure) NEJM (2023) Supplementary Material Jastreboff et al
US$ 26.33
US$ 24.27
US$ 22.21
US$ 25.48
US$ 20.83
US$ 23.16
